https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE Study https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:14133 Wed 11 Apr 2018 16:56:23 AEST ]]> Phase I trial of hypofractionated chemoradiotherapy in the palliative management of esophageal and gastro-esophageal cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51990 Tue 26 Sep 2023 10:53:57 AEST ]]> Paragon (ANZGOG-0903): phase 2 study of Anastrozole in women with estrogen or progesterone receptor-positive platinum-resistant or -refractory recurrent ovarian cancer https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34256 Mon 25 Feb 2019 11:25:06 AEDT ]]> A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18630 Mon 20 Jul 2015 16:38:11 AEST ]]>